Skip Navigation


Annals of Oncology Advance Access originally published online on July 12, 2005
Annals of Oncology 2005 16(11):1848-1849; doi:10.1093/annonc/mdi356
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
16/11/1848    most recent
mdi356v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (6)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Moroni, M.
Right arrow Articles by Siena, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moroni, M.
Right arrow Articles by Siena, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology

Letter to the Editor

Somatic mutation of EGFR catalytic domain and treatment with gefitinib in colorectal cancer

The first 10% of the full text of this article appears below.

In non-small-cell lung cancer, response to the small molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors gefitinib or erlotinib is associated with activating mutations including in-frame deletions and amino acids substitutions in exons 18, 19 and 21 in the catalytic domain of EGFR gene [1Go].

We have demonstrated recently that clinical response of metastatic . . . [Full Text of this Article]

M. Moroni1, A. Sartore-Bianchi1, S. Benvenuti2, S. Artale1, A. Bardelli2,3 and S. Siena1,*

1 Falck Division of Medical Oncology, Ospedale Niguarda Ca' Granda Milan and 2 Oncogenomics Center, Institute for Cancer Research and Treatment (IRCC), University of Torino Medical School, Candiolo; 3 FIRC Institute of Molecular Oncology (IFOM), Milan, Italy

* E-mail: salvatore.siena@ospedaleniguarda.it


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JNCI J Natl Cancer InstHome page
S. Siena, A. Sartore-Bianchi, F. Di Nicolantonio, J. Balfour, and A. Bardelli
Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor-Targeted Therapy in Metastatic Colorectal Cancer
J Natl Cancer Inst, October 7, 2009; 101(19): 1308 - 1324.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
I Chau, D Cunningham, T Hickish, A Massey, L Higgins, R Osborne, N Botwood, and A Swaisland
Gefitinib and irinotecan in patients with fluoropyrimidine-refractory, irinotecan-naive advanced colorectal cancer: a phase I-II study
Ann. Onc., April 1, 2007; 18(4): 730 - 737.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. L. Kwak, J. Jankowski, S. P. Thayer, G. Y. Lauwers, B. W. Brannigan, P. L. Harris, R. A. Okimoto, S. M. Haserlat, D. R. Driscoll, D. Ferry, et al.
Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas.
Clin. Cancer Res., July 15, 2006; 12(14): 4283 - 4287.
[Abstract] [Full Text] [PDF]